	US 12,128,031 B2
	Method of improving psychosocial health
Alon Seifan, New York, NY (US)
Assigned to HB Biotech, Inc., New York, NY (US)
Filed by HB Biotech, Inc., New York, NY (US)
Filed on Jun. 6, 2023, as Appl. No. 18/206,559.
Application 18/206,559 is a continuation of application No. 17/996,413, previously published as PCT/US2021/027641, filed on Apr. 16, 2021.
Claims priority of provisional application 63/111,156, filed on Nov. 9, 2020.
Claims priority of provisional application 63/011,932, filed on Apr. 17, 2020.
Prior Publication US 2023/0310383 A1, Oct. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4184 (2006.01); A61K 31/277 (2006.01); A61K 33/08 (2006.01); A61K 45/06 (2006.01); A61P 25/22 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/4184 (2013.01) [A61K 31/277 (2013.01); A61K 33/08 (2013.01); A61K 45/06 (2013.01); A61P 25/22 (2018.01); A61P 25/28 (2018.01)]

6 Claims

1. A method of improving psychosocial health in a human in need thereof, the method comprising:

orally administering an effective amount of a calcium channel blocker (CCB) selected from the group consisting of anipamil, devapamil, falipamil, gallopamil, tiapamil, and verapamil; and

orally co-administering an effective amount of an angiotensin II receptor blocker (ARB) selected from the group consisting of telmisartan and candesartan; and

wherein the human is in need of improvement in three or more factors of psychosocial health selected from the group consisting of (i) meaning and purpose, (ii) emotional support, (iii) instrumental support, (iv) friendship, and (v) loneliness; and

wherein the human does not have a neurodegenerative disorder.